secwatch.observer — SEC 8-K summary
======================================

Issuer:     Passage BIO, Inc. (PASG)
CIK:        0001787297
Form:       8-K
Filed at:   2024-10-24T23:59:59+00:00
Accession:  0001558370-24-013563
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PBFT02 delivers superior CSF progranulin with AAV1 vector; interim safety and biomarker data promising
--------------------------------------------------------------------------------

- Capsid comparison in NHPs: AAV1 vector achieved superior human PGRN levels in CSF versus AAV5 and AAVhu68 after ICM administration.
- In Grn knockout mice, PBFT02 improved lysosomal histopathology and reduced neuroinflammation across brain regions.
- Interim clinical data from upliFT-D trial: Dose 1 well-tolerated; durable CSF progranulin increases sustained up to 12 months.
- NHP biodistribution showed ICM administration of PBFT02 achieved high gene distribution to cortical and sub-cortical brain regions and spinal cord.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787297/000155837024013563/0001558370-24-013563-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787297/000155837024013563/pasg-20241024x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-013563

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer